Amgen Repatha pricing sees a 60% reduction in the U.S. through a new program, enhancing market access.
• Amgen reduces Repatha price by 60% for U.S. patients.
• New program targets direct-to-patient access and government programs.
• Move aligns with U.S. drug cost reduction efforts.
Amgen has announced a significant reduction in the price of its cholesterol medication, Repatha, by more than half for U.S. patients. This move is part of a new medication-access initiative called AmgenNow, which aims to provide direct-to-patient pricing. The program offers Repatha at $239 per month, representing a 60% decrease from the current U.S. list price. This pricing strategy is also extended to participants in government programs such as Medicare and Medicaid. The decision aligns with the Trump administration’s call to lower prescription drug costs through direct-to-consumer pricing and international price benchmarking.
Repatha, an injectable medication, is used to lower low-density lipoprotein (LDL) cholesterol and reduce the risk of heart-related issues, including heart attacks and strokes. By implementing this pricing strategy, Amgen aims to enhance market access and affordability for patients who require this medication. The company’s initiative is expected to have a significant impact on the market, potentially influencing other pharmaceutical companies to adopt similar strategies.
The reduction in Repatha’s price comes at a time when the pharmaceutical industry faces increasing pressure to address high drug costs. Amgen’s approach may set a precedent for other companies, encouraging them to explore innovative pricing models that prioritize patient access and affordability. The move could also affect the competitive landscape, as rival companies may need to adjust their pricing strategies to remain competitive.
Moreover, this development highlights the ongoing efforts within the industry to balance profitability with patient needs. As drug prices continue to be a focal point of public and governmental scrutiny, companies like Amgen are exploring ways to align their business practices with broader healthcare objectives.
For more insights on market access strategies and updates, visit our Market Access section.